 Phase 1 study showed some patients with relapsed acute myeloid leukemia AML or myelodysplastic syndrome MDS achieved a remission with APVO436 after failing 1-8 lines of prior therapies Data was published in the prestigious oncology journal Cancers SEATTLE, WA ACCESSWIRE August 17, 2021 Aptevo Therapeutics Inc. Aptevo or the Company NASDAQ:APVO, a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIRTM and ADAPTIR-FLEXTM platform technologies, today announced the publication of a peer-reviewed research article in the prestigious oncology journal Cancers . The research article reports the results of a multi-institutional Phase 1 clinical study of Aptevos lead leukemia drug candidate APVO436 in 46 adult patients with relapsed or refractory AML or MDS. 